Drugs/Medical Archive

When Tardive Dyskinesia isn’t just a phase you’ll grow out of…

January 12th, 2010. By AbiK

Greek progressive math-death metallers Tardive Dyskinesia signed with Coroner Records for the release of their second album entitled “The Sea Of See Through Skins”, scheduled for the beginning of October. The album, presented as an experimental and hypnotic trip into an obsessive and structurated world, features an incredible technical approach and an overload of math structures and tempos.

And so there you have it. Yes, there is a band out there that, in all their blue-sky brainstorming for a band name, came up with “Tardive Dyskinesia” as their very own.

I’m trying to envision that session…(note, the band members hail from Greece, so my lingo may be slightly off, but…)

“Hey dude, how bout Epileptic Overdrive?”

“Nah…I mean it’s good man, but it doesn’t speak to the cause and effect…you know, like something’s gotta send you on the trip…”

And somehow someone somewhere came across the condition of Tardive Dyskinesia. All the elements were there. Drug-induced. Not natural. Physically altering. No control. In fact, completely out of control. The ultimate taking over of your body…and hence your mind… That’s it, man.

Here, this is straight from the band’s website:

Here we are: 2003 and the beginning of their more creative period. The change in sound brought about a change in name too: Tardive Dyskinesia (an illness caused by long-term use of psychotropic medication that manifests itself in involuntary, repetitive movements of the limbs).

That’s all they really say about it. And I guess not much more is needed from a fan’s perspective.

But if you’ve been suffering from Tardive Dyskinesia—the real condition, that is—you might question why anyone would want to brand themselves with it–and start pumping out the requisite t-shirts and buttons to promote it. And I guarantee you that the only way some listeners know what the heck the name really means is by happenstance: Read the rest of this entry »

Tags: Reglan, Tardive Dyskinesia
Posted in Drugs/Medical | 2 Comments »

Vaccines: Just in Time for Big Pharma

January 1st, 2010. By janem

Big Pharma breathed a big sigh of relief when it realized vaccines can give a lot more bang for the buck than many “blockbuster” drugs. For pharmaceutical companies like Wyeth (now owned by Pfizer), Glaxo, Sanofi-Aventis and Novartis AG, pandemic flu threats–H1N1 in particular–couldn’t have come at a better time.

For instance, Wyeth’s pediatric pneumococcal vaccine Prevnar makes over $3 billion in annual sales–that should help cover product liability claims for its diet drug Fen-phen. (To date, the drug giant has set aside $21 billion to cover claims.)

And Merck & Co, already making shingles and cervical cancer vaccines, recently got into the US market via a deal to distribute seasonal flu vaccine made by Australia’s CSL Ltd, just in time to pay $4.85 billion in its Vioxx claims.

“Vaccines, vaccines, wonderful business,” quipped Chris Viehbacher, CEO of Sanofi-Aventis, which anticipates earnings of $6 billion in vaccine revenues this year and double its sales by 2013. In the last quarter of 2009, its H1N1 vaccines sales reached $500 million.

Novartis expected to generate $700m in fourth-quarter sales alone from its H1N1 vaccine, but GlaxoSmithKline is the main player in vaccines, holding 22 percent of the global market, and is set to cash in with Brazil, China and India as their burgeoning economies spell bigger budgets for healthcare spending. Glaxo is betting big time on the vaccine business: it just purchased a vaccine operation in Quebec for $1.4 billion, which may tighten the purse strings after paying almost $1billion to resolve lawsuits over its antidepressant Paxil.

Other big spenders are Abbott Laboratories ($6.6 billion on Belgian flu vaccine maker Solvay) and Johnson & Johnson (it just bought 18 percent of Dutch vaccine firm Crucell). “More companies are investing in vaccines as a way of diversifying away from prescription drugs,” says Michael Boyd of the International Federation of Pharmaceutical Manufacturers & Associations. “New technologies, such as cell culture, are enabling them to produce more sophisticated vaccines.”

With nearly 1 billion doses of H1N1 vaccine ordered in 2009, analysts predict the global vaccine industry will reach $40 billion by 2012: Cha ching. Perhaps this means we won’t see so many “blockbuster” new drugs entering the market in the next few years. After all, product liability litigation has been expensive.

Tags: Big Pharma, flu vaccine, H1N1, H1N1 flu, H1N1 Vaccine, vaccine
Posted in Drugs/Medical | 4 Comments »

Did Yasmin Clinical Trials Lack Female Researchers?

December 27th, 2009. By janem

Historically, clinical trials have studied more males than females, and researchers–for several reasons–test mostly or exclusively men. The Yasmin manufacturer says the effectiveness and safety of Yasmin was established in large-scale clinical trials: it involved 2,629 women. This number may seem substantial, but Viagra was given to over 3,000 men (of course) during its clinical trials and the statin Lipitor (prescribed for both sexes) involved 16,066 patients!

Biomedical scientists and researchers have preferred studying male subjects for a number of reasons including:

• The outdated belief that women were just little men and that the only difference was in reproductive organs;
• Perceived costs and complexity of recruitment and inclusion of women in clinical trials;
• The desire both to protect a woman’s potential fetus (regardless of whether she is pregnant, uses contraceptives, or intendsto conceive) and to avoid legal liability from prenatal exposure.
• The potentially confounding effects of women’s hormonal changes.

Clearly, a drug that is taken daily by millions of women-such as Yasmin and Yaz-needs more exhaustive clinical trials. Perhaps the (predominantly male) researchers are biased: they won’t ever take a birth control pill but they might use Viagra or a cholesterol-lowering drug like Lipitor or Crestor, the most widely prescribed medications in the world.

In the recently published book The Push to Prescribe, the authors make it clear that the under-representation–or even complete lack–of women in pharmaceutical research is one reason why women should research a drug such as Yasmin beforehand, even though they trust their doctors.

“Women are at the brunt of bad prescribing practices,” says Alan Cassels, a drug policy researcher. “Historically, it goes back to the birth control pill…Women are the leading consumers of health products, not just for themselves but for their husbands and kids as well.”

The Push to Prescribe also points out that adverse reactions to drugs are a major issue of particular interest to women. The number of people exposed to drugs is much more once it has been approved, meaning that experiences other than those observed in clinical trials are likely to occur after a drug is on the market.

Tags: Yasmin, yasmin clinical trials, Yaz
Posted in Drugs/Medical | No Comments »

Hospital Parting Gifts? MRSA and a $60k tab…

December 21st, 2009. By AbiK

A lot of websites have an “editorial calendar” that they try to stick to. But when you’re site also relies on the news-of-the-minute, well, coincidences occur—and one just happened at LawyersAndSettlements.com. Earlier today, we published an interview Jane did with an MRSA victim, David. No sooner had I read the interview, and right there in my inbox were the results of a study on post-surgery MRSA infection and its associated costs. (And David may have gotten off cheap, believe it or not).

It seems, according to the Public Library of Science journal PLoS ONE, Duke University Medical Center conducted a study that examined the 90-day post-operative outcomes of 659 patients whose incisions had either become infected with methicillin-resistant Staphylococcus aureus (MRSA) or with methicillin-susceptible Staphylococcus aureus (MSSA). Some of the 659 patients had no infection.

Here’s what they found… Read the rest of this entry »

Tags: Hospital Infection, MRSA, MSSA
Posted in Drugs/Medical | 2 Comments »

Underdosing or Overdosing Heparin—A Nurse’s Nightmare?

December 18th, 2009. By janem

I wouldn’t want to be a nurse administering heparin and I wouldn’t be surprised if seasoned nurses are reluctant to inject their patients with the blood thinner.

Most everyone is familiar with the incident that happened with actor Dennis Quaid’s twins: in 2007 a nurse picked up the wrong bottles of Heparin and the newborns were given an overdose that almost killed them. The “tired” nurse was blamed, and now Quaid has launched a campaign for better bottle-labeling systems. Wouldn’t better labeling be the responsibility of the drug manufacturer?

In October, US officials announced that heparin’s potency will be reduced by about 10 percent. So some patients will receive a higher-than-usual dose or number of units of heparin. (Sounds like good news for the manufacturer-unless the price of heparin drops by 10 percent. ) According to the FDA, recommended doses of heparin described in the drug’s label have not changed, and it does not recommend that clinicians increase a patient’s heparin dose to compensate for the reduced potency. Does that mean a patient has a higher risk of blood clots?

Researchers at the University of Oxford say that the risk of having a potentially fatal blood clot after surgery is higher and lasts for longer than had previously been thought. What if a patient isn’t given enough of the low-dosage heparin?

It’s very confusing.

According to HealthDay News, the decrease in potency will make it easier to spot impurities. The new lots will be identified by either the letter “N” placed next to the lot number or expiration date (three manufacturers) or a numeric code (one manufacturer). Got that?

Officials say that the correct dosing of heparin “has always been highly individualized and requires intense monitoring, which is a protocol that will remain in effect.” Dr. Dwaine Rieves, director of the FDA’s Center for Drug Evaluation and Research Division of Medical Imaging and Hematology Products, said, ”The use of heparin is closely tied into monitoring and doses adjusted based on that.”  If I were a nurse, I’d be thinking about Quaid’s twins who were given too much heparin; I’d be thinking about amputee James Bradley, who was given too much.

Tags: Heparin
Posted in Drugs/Medical | No Comments »